NEW YORK (GenomeWeb News) - Invitrogen has licensed cell proliferation assay technology from Harvard University that it will use in its click chemistry technology-related programs, the company said today.
The company said it is adding the Harvard technology to its click chemistry IP portfolio, which includes a license from the Scripps Research Institute and agreements with the University of California, Berkeley, the California Institute of Technology, and the National Institutes of Health.
Those licenses are for marketing Click-iT kits for glycoprotein profiling that allow researchers to label glycoprotein subsets in live cells and in extracts or purified samples.
The license for Harvard’s IP will allow Invitrogen’s researchers “to examine cell proliferation in parallel with other biomarkers,” Invitrogen VP and GM of Cellular Analysis Augie Sick said in a statement.
This ability will enhance the “power of this fundamental method for assessing cell health, determining genotoxicity and evaluating anti-cancer drugs,” Sick continued.
The company also said it is developing new click chemistry applications, such as protein synthesis detection. Invitrogen said the click technology is suitable for flow cytometry, fluorescence microscopy, and high-content screening.
Financial terms of the agreement were not released.